Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

531 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.
Patel KR, Nguyen PL, Proudfoot JA, Liu Y, Pra AD, Spratt DE, Pollack A, Sandler HM, Efstathiou JA, Lawton C, Simko JP, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Pugh SL, Davicioni E, Tran PT, Feng FY. Patel KR, et al. Among authors: feng fy. Eur Urol Oncol. 2024 Nov 13:S2588-9311(24)00246-3. doi: 10.1016/j.euo.2024.10.017. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39542826
Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation.
Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L, Olson KB, Sandler HM, Hamstra DA. Sabolch A, et al. Among authors: feng fy. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e351-60. doi: 10.1016/j.ijrobp.2011.01.063. Epub 2011 Apr 13. Int J Radiat Oncol Biol Phys. 2011. PMID: 21493015
The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA. Shilkrut M, et al. Among authors: feng fy. Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14. Cancer. 2013. PMID: 22893254 Free article.
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.
Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY. Jackson WC, et al. Among authors: feng fy. Radiat Oncol. 2013 Jul 8;8:170. doi: 10.1186/1748-717X-8-170. Radiat Oncol. 2013. PMID: 23835115 Free PMC article.
531 results